secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beyond Air, Inc. (XAIR)
CIK:        0001641631
Form:       8-K
Filed at:   2023-08-15T23:59:59+00:00
Accession:  0001493152-23-028715
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beyond Air Q1 FY2024 revenue $0.1M (first commercial); net loss $14.1M; secured $40M debt facility
--------------------------------------------------------------------------------

- Revenue of $0.1M from commercial LungFit PH sales; cost of revenue $0.3M.
- Net loss $14.1M ($0.45 loss per share) vs $10.9M ($0.37) YoY; R&D $4.7M, G&A $10.9M.
- Secured up to $40M debt financing from Avenue Capital; $17.5M drawn; cash $57M.
- In excess of $1M annual commercial LungFit PH contracts; CE Mark expected by end 2023.
- Agreed with FDA on VCAP study for 2023-24 winter; added nNOS program for autism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641631/000149315223028715/0001493152-23-028715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641631/000149315223028715/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-028715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer